Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results

Arcturus Therapeutics (NASDAQ:ARCT) released its quarterly earnings data on Thursday. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78), Zacks reports. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million.

Arcturus Therapeutics Trading Down 8.9 %

ARCT opened at $14.55 on Friday. The business’s 50 day moving average is $16.95 and its 200-day moving average is $18.59. The stock has a market cap of $394.12 million, a PE ratio of -6.55 and a beta of 2.96. Arcturus Therapeutics has a twelve month low of $14.11 and a twelve month high of $45.00.

Wall Street Analysts Forecast Growth

ARCT has been the topic of a number of analyst reports. BTIG Research initiated coverage on Arcturus Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $41.00 target price on the stock. Wells Fargo & Company decreased their price target on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday. Finally, HC Wainwright decreased their price target on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research note on Friday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $61.40.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.